ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Sells $1,941,563.19 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 33,481 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the transaction, the chief executive officer now owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. This trade represents a 8.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

ANI Pharmaceuticals Trading Down 3.6 %

Shares of ANIP stock opened at $57.23 on Friday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The stock has a 50-day simple moving average of $58.26 and a 200 day simple moving average of $60.74. ANI Pharmaceuticals, Inc. has a fifty-two week low of $48.20 and a fifty-two week high of $70.81. The stock has a market capitalization of $1.20 billion, a P/E ratio of -104.05 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. During the same quarter in the previous year, the company posted $1.05 EPS. The business’s revenue was up 12.5% compared to the same quarter last year. On average, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on ANIP shares. Truist Financial increased their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. Piper Sandler began coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Finally, Raymond James boosted their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $77.33.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ANIP. Vanguard Group Inc. grew its holdings in shares of ANI Pharmaceuticals by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company’s stock worth $90,314,000 after acquiring an additional 17,460 shares during the last quarter. State Street Corp increased its stake in ANI Pharmaceuticals by 9.1% in the 3rd quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company’s stock worth $41,991,000 after purchasing an additional 58,698 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in ANI Pharmaceuticals by 3.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company’s stock worth $40,132,000 after buying an additional 21,053 shares during the period. Pacer Advisors Inc. lifted its stake in ANI Pharmaceuticals by 23,259.8% during the third quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock valued at $33,907,000 after buying an additional 565,910 shares in the last quarter. Finally, Global Alpha Capital Management Ltd. boosted its holdings in shares of ANI Pharmaceuticals by 1.8% in the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock worth $32,005,000 after buying an additional 9,500 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.